Share on StockTwits

Stock analysts at Chardan Capital dropped their price objective on shares of Endocyte (NASDAQ:ECYT) from $26.00 to $15.00 in a report issued on Wednesday. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target would indicate a potential upside of 94.30% from the stock’s previous close.

A number of other analysts have also recently weighed in on ECYT. Analysts at RBC Capital cut their price target on shares of Endocyte from $20.00 to $15.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at Citigroup Inc. initiated coverage on shares of Endocyte in a research note on Thursday, June 5th. They set a “neutral” rating and a $8.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Endocyte presently has a consensus rating of “Buy” and a consensus target price of $24.28.

Endocyte (NASDAQ:ECYT) opened at 7.72 on Wednesday. Endocyte has a 1-year low of $6.01 and a 1-year high of $33.70. The stock’s 50-day moving average is $7.57 and its 200-day moving average is $12.8. The company’s market cap is $320.4 million.

Endocyte (NASDAQ:ECYT) last released its earnings data on Friday, May 2nd. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.05. The company had revenue of $17.30 million for the quarter, compared to the consensus estimate of $15.07 million. On average, analysts predict that Endocyte will post $-0.19 earnings per share for the current fiscal year.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.